retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces Liver Fat Content by 86% Retatrutide Explained: The Triple Agonist

Lilly and Novo Nordisk, which makes rival weight-loss drugs, struck deals with several telehealth companies in what they described as an effort to transition patients who were on compounded versions of their drugs to the name-brand version

Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take semaglutide

The need-to-know this morning Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting that the drug led to significant weight loss in a mid-stage trial

A high-quality protein shake between meals adds 25-30 grams of protein without requiring a large volume of food

PloS one, 5(9), e12734.

Since the glucose-lowering effects of GIP have been shown to be impaired in patients with T2D, interest has focused on developing antidiabetic therapies based upon the actions of GLP-1 and GIP, the response to which remains intact. To continue reading Log in or register to continue reading